PACIFICHEALTH LABORATORIES INC - FORM 8-K - EX-99.1

Attached files

file	filename
8-K - PACIFICHEALTH LABORATORIES INC	v230841_8k.htm

Exhibit 99.1

For Immediate Release:

Contact:

Stephen Kuchen, CFO

732-739-2900, x603

skuchen@pacifichealthlabs.com

PACIFICHEALTH LABORATORIES ANNOUNCES 2ND QUARTER EARNINGS;

FIRST HALF PROFITS UP $251,504 VERSUS 2010

MATAWAN, NJ, August 4, 2011 – PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading sports nutrition company, today reported its financial results for the quarter and six months ended June 30, 2011.

Second Quarter & First Half 2011 vs. 2010 Financial Results

Revenues were $2,245,226 for the second quarter and $3,976,837 for the first six months of 2011 compared to $2,554,306 and $4,204,571, respectively, for the same periods in 2010. Net income for the second quarter was $91,769, or $0.00 per diluted share, and $118,999, or $0.01 per diluted share, for the first six months of 2011 compared to net income of $136,725, or $0.01 per diluted share, and a net loss of ($132,505), or ($0.01) per diluted share, for the same periods in 2010. General and administrative expenses decreased $222,953, or 30%, to $511,490 in the second quarter and $460,119, or 30%, to $1,048,474 for the first six months of 2011 compared to the same periods in 2010 primarily as a result of a reduction in personnel and personnel related expenses.

At June 30, 2011, the Company had cash, cash equivalents, and other short-term investments of $1,361,515 compared to $284,165 at December 31, 2010 primarily due to the two private placements completed in 2011.

Fred Duffner, President and CEO of PacificHealth Laboratories, said, “Revenues for the second quarter are not reflective of the progress we have made in 2011. The 5% decline in overall year to date revenues was primarily a result of a change in one of our top customers’ inventory and promotional patterns. Last year they front loaded their promotions in the first half of the year and in 2011 they are spreading their promotions throughout the year. This plus the loss of sales of the discontinued FORZE™ products were the major contributors to the revenue declines during the second quarter and year to date.”

Mr. Duffner added, “During the quarter we launched our new advertising campaign supporting all of our core brands as well as our new products ACCEL RECOVER™ bar and 2ND SURGE® energy gel in leading endurance magazines. Both ACCEL RECOVER and 2ND SURGE are now distributed in over 400 sports specialty retail outlets and major web sites including Performance and Road Runner stores. Starting in July the new brands were being sold in the top 1000 GNC stores. Ecommerce continues to be a strong growth area for us. To support this growth, we hired an e-commerce web manager, re-launched our website, and implemented a number of initiatives

- more -

on Facebook and Twitter. We are already seeing results in terms of Internet sales. As a company, we are challenged to maintain profits in the face of increased cost of goods, particularly protein and packaging. Costs of goods for the quarter were up 3.4 percent and 2.2 percent year to date. This increase impacted second quarter profits by approximately $76,000 and $88,000 year to date.”

Mr. Duffner concluded, “We have made the fundamental changes in our business needed to regain our leadership position in endurance sports nutrition. Our balance sheet is strong and I am confident that our continued investment in new products, e-commerce, advertising and promotion will drive future growth and profits.”

About PacificHealth Laboratories. Inc.

PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI’s principal areas of focus include sports performance and weight loss. To learn more, visit www.pacifichealthlabs.com.

Notice: This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects," "plans," "will,, "estimates," "forecasts," "projects," or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.

- more -

SELECTED FINANCIAL DATA:

PACIFICHEALTH LABORATORIES, INC.
STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2011 AND 2010
(UNAUDITED)

	Three Months						Six Months
	Ended June 30,						Ended June 30,
	2011			2010			2011			2010
Revenues:
Net product sales	$	2,245,226		$	2,554,306		$	3,976,837		$	4,204,571

Cost of goods sold		1,250,510			1,336,291			2,211,502			2,245,670

Gross profit		994,716			1,218,015			1,765,335			1,958,901

Operating expenses:
Sales and marketing		378,612			349,262			569,043			584,347
General and administrative (Includes related party consulting
of $48,000, $0, $91,000 and $0, respectively)		511,490			734,443			1,048,474			1,508,593
Research and development		9,978			-			24,795			-
		900,080			1,083,705			1,642,312			2,092,940

Income (loss) before other (expense) income and
provision for income taxes		94,636			134,310			123,023			(134,039	)

Other (expense) income:
Other income		-			4,000			2,100			4,000
Interest income		127			277			279			505
Interest expense		(2,994	)		(1,862	)		(6,403	)		(2,971	)
		(2,867	)		2,415			(4,024	)		1,534

Income (loss) before provision for income taxes		91,769			136,725			118,999			(132,505	)

Provision for income taxes		-			-			-			-

Net income (loss)	$	91,769		$	136,725		$	118,999		$	(132,505	)

Basic income (loss) per share	$	0.00		$	0.01		$	0.01		$	(0.01	)

Diluted income (loss) per share	$	0.00		$	0.01		$	0.01		$	(0.01	)

Weighted average common shares - basic		19,723,499			16,039,606			18,202,826			15,862,791

Weighted average common shares - diluted		19,929,921			16,039,606			18,390,201			15,862,791

- more -

PACIFICHEALTH LABORATORIES, INC.
BALANCE SHEETS
(UNAUDITED)

	June 30,			December 31,
	2011			2010
ASSETS
Current assets:
Cash and cash equivalents	$	1,286,515		$	134,165
Other short-term investments		75,000			150,000
Accounts receivable, net		981,897			416,722
Inventories, net		1,060,138			596,317
Prepaid expenses		173,522			64,780
Total current assets		3,577,072			1,361,984

Property and equipment, net		31,421			52,531

Deposits		10,895			10,895

Total assets	$	3,619,388		$	1,425,410

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Line of credit	$	37,500		$	75,000
Notes payable		58,761			20,670
Accounts payable and accrued expenses (Includes related
party of $91,000 and $11,000, respectively)		1,645,320			713,184
Deferred revenue		75,286			60,836
Total current liabilities		1,816,867			869,690

Stockholders' equity:
Common stock, $.0025 par value; authorized
50,000,000 shares; issued and outstanding:
20,865,257 and 16,485,257 shares, respectively		52,163			41,213
Additional paid-in capital		21,279,821			20,162,969
Accumulated deficit		(19,529,463	)		(19,648,462	)

		1,802,521			555,720

Total liabilities and stockholders' equity	$	3,619,388		$	1,425,410

# # #

Attached files

Stock widget

Investing forum

PACIFICHEALTH LABORATORIES INC Reports